StocksFundsScreenerSectorsWatchlists
OCGN

OCGN - Ocugen Inc Stock Price, Fair Value and News

1.78USD+0.05 (+2.89%)Market Closed

Market Summary

OCGN
USD1.78+0.05
Market Closed
2.89%

OCGN Stock Price

View Fullscreen

OCGN RSI Chart

OCGN Valuation

Market Cap

456.6M

Price/Earnings (Trailing)

-6.05

EV/EBITDA

-1.07

Price/Free Cashflow

-5.9

MarketCap/EBT

-1.7

OCGN Price/Sales (Trailing)

OCGN Profitability

Return on Equity

-129.33%

Return on Assets

-101.12%

Free Cashflow Yield

-16.96%

OCGN Fundamentals

OCGN Earnings

Earnings (TTM)

-75.5M

Earnings Growth (Yr)

35.4%

Earnings Growth (Qtr)

38.22%

Breaking Down OCGN Revenue

Last 7 days

51.9%

Last 30 days

72.6%

Last 90 days

264.4%

Trailing 12 Months

16.9%

How does OCGN drawdown profile look like?

OCGN Financial Health

Current Ratio

5.08

Debt/Equity

0.03

Debt/Cashflow

-45.26

OCGN Investor Care

Shares Dilution (1Y)

17.18%

Diluted EPS (TTM)

-0.33

Tracking the Latest Insider Buys and Sells of Ocugen Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 03, 2024
musunuri shankar
sold (taxes)
-117,673
0.653
-180,204
chief executive officer
Jan 03, 2024
upadhyay arun
sold (taxes)
-27,186
0.653
-41,633
see remarks
Sep 16, 2023
upadhyay arun
sold (taxes)
-345
0.41
-842
see remarks
Jun 16, 2023
upadhyay arun
sold (taxes)
-467
0.51
-917
chief scientific officer
Jun 14, 2023
zhang junge
bought
99,998
0.4993
200,278
-
Feb 16, 2023
musunuri shankar
sold
-108,000
1.08
-100,000
chief executive officer
Feb 16, 2023
musunuri shankar
acquired
33,000
0.33
100,000
chief executive officer
Jan 17, 2023
musunuri shankar
acquired
51,000
0.51
100,000
chief executive officer
Jan 17, 2023
musunuri shankar
sold
-128,000
1.28
-100,000
chief executive officer
Jan 03, 2023
musunuri shankar
sold (taxes)
-47,346
1.25
-37,877
chief executive officer

1–10 of 50

Which funds bought or sold OCGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC Financial Services Group, Inc.
sold off
-100
-400
-
-%
Mar 11, 2024
VANGUARD GROUP INC
added
0.96
2,152,730
6,922,950
-%
Mar 04, 2024
VIMA LLC
new
-
210
210
-%
Feb 26, 2024
Virtu Financial LLC
sold off
-100
-14,000
-
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
98.83
70,000
108,000
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
unchanged
-
18.00
58.00
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
new
-
33,000
33,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
reduced
-93.19
-69,925
7,583
-%
Feb 15, 2024
GTS SECURITIES LLC
new
-
6,281
6,281
-%
Feb 15, 2024
LUMINUS MANAGEMENT LLC
reduced
-40.26
-153,777
935,285
0.26%

1–10 of 43

Are Funds Buying or Selling OCGN?

Are funds buying OCGN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own OCGN
No. of Funds

Unveiling Ocugen Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
4.69%
12,039,918
SC 13G/A
Jan 22, 2024
state street corp
0.33%
835,826
SC 13G/A
Jul 07, 2023
blackrock inc.
1.5%
3,907,414
SC 13G/A
Feb 10, 2023
state street corp
13.76%
30,121,024
SC 13G/A
Feb 09, 2023
vanguard group inc
5.42%
11,859,143
SC 13G/A
Feb 01, 2023
blackrock inc.
6.9%
15,061,361
SC 13G/A
Apr 11, 2022
state street corp
13.57%
29,153,704
SC 13G/A
Feb 11, 2022
state street corp
7.04%
14,017,619
SC 13G
Feb 04, 2022
blackrock inc.
6.5%
12,931,131
SC 13G
Feb 10, 2021
vanguard group inc
5.60%
9,074,993
SC 13G

Recent SEC filings of Ocugen Inc

View All Filings
Date Filed Form Type Document
Mar 21, 2024
8-K
Current Report
Mar 20, 2024
8-K
Current Report
Mar 20, 2024
3
Insider Trading
Mar 20, 2024
3
Insider Trading
Mar 18, 2024
8-K
Current Report
Feb 21, 2024
8-K
Current Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Jan 22, 2024
SC 13G/A
Major Ownership Report
Jan 08, 2024
8-K
Current Report
Jan 05, 2024
4
Insider Trading

Peers (Alternatives to Ocugen Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Ocugen Inc News

Latest updates
MarketWatch36 hours ago
InvestorsObserver26 Mar 202410:43 am
MarketWatch25 Mar 202410:33 pm
InvestorPlace25 Mar 202408:03 pm
TradingView25 Mar 202402:47 pm
InvestorsObserver25 Mar 202412:24 pm
Seeking Alpha21 Mar 202406:40 pm

Ocugen Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-16.1%75.0089.0096.0010911613014210611612454.0027.0021.0024.0012.0017.0024.004.0015.002.0011.00
  Current Assets-23.0%57.0073.0084.0098.0010712313810311312251.0026.0020.0023.0011.0016.0023.003.008.002.006.00
    Cash Equivalents-24.2%54.0071.0068.0078.0010211513095.0010711645.0024.0019.0015.003.008.0015.001.000.002.002.00
  Net PPE23.5%14.0012.008.006.005.003.002.001.00--1.001.000.000.000.000.000.000.000.000.004.00
Liabilities-12.9%16.0019.0020.0025.0021.0016.0011.0010.009.008.007.006.006.009.005.006.0037.0010.0020.0015.0021.00
  Current Liabilities-17.3%11.0013.0016.0018.0015.0010.008.007.006.005.004.004.004.007.003.005.0035.009.002.0014.009.00
  Short Term Borrowings-----------0.000.001.004.00---2.001.007.00-
  Long Term Debt1.6%1.001.001.002.002.002.002.002.002.002.002.002.002.002.002.001.001.001.00-1.00-
    LT Debt, Current0.8%1.001.001.00------------------
    LT Debt, Non Current1.6%1.001.001.002.002.002.002.002.002.002.002.002.002.002.002.001.001.001.00-1.00-
Shareholder's Equity-16.9%58.0070.0076.0084.0095.0011413196.0010711646.0022.0014.0015.007.0011.00-----
  Retained Earnings-5.6%-266-252-229-213-191-169-149-131-117-106-80.38-73.30-69.50-59.04-55.40-51.48-63.86-41.09-22631.00-216
  Additional Paid-In Capital0.7%32232030329528428127922622222112593.0082.0072.0062.0062.0051.0035.0022018.00206
Shares Outstanding0.0%256256226222213216206199194196186184---------
Float------483---1,600---29.00---18.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations27.1%-13,706-18,806-18,240-16,914-14,302-13,797-15,066-12,804-8,053-21,801-5,283-4,283-2,653-3,087-4,686-8,743-2,118-3,363-2,667-2,786-3,081
  Share Based Compensation-17.4%2,1742,6322,6892,6682,4952,0793,2992,6831,3472,095833163126149222164193112415329226
Cashflow From Investing-158.8%-3,3655,7233,441-15,295-83.00-1,366-223-192-350-1,013-261-251-22.0019.00-53.00-20.87-2,204-121-10.58--793*
Cashflow From Financing-100.2%-35.0015,4045,4968,17596223650,10260511093,66426,2979,4676,81314,84348890718,9453,8551,3591,931-706

OCGN Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses    
Research and development$ 6,342$ 15,622$ 30,069$ 32,544
General and administrative9,0827,49726,83928,174
Total operating expenses15,42423,11956,90860,718
Loss from operations(15,424)(23,119)(56,908)(60,718)
Other income (expense), net1,2621,1973,3231,306
Net loss(14,162)(21,922)(53,585)(59,412)
Other comprehensive income (loss)    
Foreign currency translation adjustment520230
Unrealized gain (loss) on marketable securities00(1)0
Comprehensive loss$ (14,157)$ (21,902)$ (53,584)$ (59,382)
Shares used in calculating net loss per common share - basic (in shares)256,492,558216,591,011240,222,667212,755,746
Shares used in calculating net loss per common share - diluted (in shares)256,492,558216,591,011240,222,667212,755,746
Net loss per share of common stock - basic (in USD per share)$ (0.06)$ (0.10)$ (0.22)$ (0.28)
Net loss per share of common stock - diluted (in USD per share)$ (0.06)$ (0.10)$ (0.22)$ (0.28)

OCGN Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 53,477$ 77,563
Marketable securities013,371
Prepaid expenses and other current assets3,0817,558
Total current assets56,55898,492
Property and equipment, net14,4696,053
Other assets3,6604,087
Total assets74,687108,632
Current liabilities  
Accounts payable2,9218,062
Accrued expenses and other current liabilities6,3999,900
Operating lease obligations540498
Current portion of long term debt1,2760
Total current liabilities11,13618,460
Non-current liabilities  
Operating lease obligations, less current portion3,1643,587
Long term debt, net1,4952,289
Other non-current liabilities497244
Total non-current liabilities5,1566,120
Total liabilities16,29224,580
Commitments and contingencies
Stockholders' equity  
Common stock; $0.01 par value; 295,000,000 shares authorized, 256,621,487 and 221,721,182 shares issued, and 256,499,987 and 221,599,682 shares outstanding at September 30, 2023 and December 31, 2022, respectively2,5662,217
Treasury stock, at cost, 121,500 shares at September 30, 2023 and December 31, 2022(48)(48)
Additional paid-in capital322,452294,874
Accumulated other comprehensive income2726
Accumulated deficit(266,603)(213,018)
Total stockholders' equity58,39584,052
Total liabilities and stockholders' equity74,687108,632
Series A Preferred Stock  
Stockholders' equity  
Preferred stock issued00
Series B Preferred Stock  
Stockholders' equity  
Preferred stock issued$ 1$ 1
OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
 CEO
 WEBSITEwww.ocugen.com
 EMPLOYEES84

Ocugen Inc Frequently Asked Questions


What is the ticker symbol for Ocugen Inc? What does OCGN stand for in stocks?

OCGN is the stock ticker symbol of Ocugen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ocugen Inc (OCGN)?

As of Wed Mar 27 2024, market cap of Ocugen Inc is 456.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OCGN stock?

You can check OCGN's fair value in chart for subscribers.

What is the fair value of OCGN stock?

You can check OCGN's fair value in chart for subscribers. The fair value of Ocugen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ocugen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OCGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ocugen Inc a good stock to buy?

The fair value guage provides a quick view whether OCGN is over valued or under valued. Whether Ocugen Inc is cheap or expensive depends on the assumptions which impact Ocugen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCGN.